1. Home
  2. MRCC vs RANI Comparison

MRCC vs RANI Comparison

Compare MRCC & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$4.76

Market Cap

135.8M

Sector

Finance

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$1.31

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
RANI
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.8M
126.8M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
MRCC
RANI
Price
$4.76
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
142.0K
715.5K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
7.81%
N/A
EPS Growth
N/A
21.05
EPS
N/A
N/A
Revenue
N/A
$1,028,000.00
Revenue This Year
N/A
$414.59
Revenue Next Year
N/A
$30.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.11
$0.39
52 Week High
$7.92
$3.87

Technical Indicators

Market Signals
Indicator
MRCC
RANI
Relative Strength Index (RSI) 37.82 46.69
Support Level $4.11 $0.46
Resistance Level $6.91 $1.54
Average True Range (ATR) 0.32 0.07
MACD -0.03 -0.00
Stochastic Oscillator 31.35 21.43

Price Performance

Historical Comparison
MRCC
RANI

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: